Zkusit zdarma
SpringWorks Therapeutics, Inc.

SpringWorks Therapeutics, Inc.

SWTX
Cena:
 
 
Valuace
70
Růst
23
Zdraví
75
Souhrn Finanční data Pro investory Předpovědi Zprávy Dividendy Zisky Návštěvnost webu Akcionáři
Souhrn
Finanční data
Pro investory
Předpovědi
Zprávy
Dividendy
Zisky
Návštěvnost webu
Akcionáři

Zprávy

Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

9:23 18-08-2025

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment...

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

European Commission Grants Approval of OGSIVEO® (nirogacestat) for the Treatment of Adults with Desmoid Tumors

9:10 18-08-2025

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment...

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

11:30 18-07-2025

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adul...

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

European Commission Grants Conditional Approval of EZMEKLY® (mirdametinib) for the Treatment of Adult and Pediatric Patients with NF1-PN

11:30 18-07-2025

– EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adul...

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors

8:00 20-06-2025

– If approved, nirogacestat will be the first and only therapy with marketing authorization in the...

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

SpringWorks Gets CHMP Nod for Mirdametinib in Rare Disease

12:26 26-05-2025

SWTX wins CHMP backing for mirdametinib in NF1-PN. EU nod is expected in the third quarter of 2025....

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN

8:00 23-05-2025

– If approved, mirdametinib is expected to be the first and only therapy in the European Union wit...

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

SpringWorks Therapeutics (SWTX) Reports Q1 Loss, Misses Revenue Estimates

18:40 09-05-2025

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks C...

Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade

Wall Street Analysts Believe SpringWorks Therapeutics (SWTX) Could Rally 42.29%: Here's is How to Trade

11:01 29-04-2025

The average of price targets set by Wall Street analysts indicates a potential upside of 42.3% in Sp...

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of SpringWorks Therapeutics, Inc. - SWTX

18:14 28-04-2025

NEW YORK , April 28, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"),...

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of SpringWorks Therapeutics, Inc.

17:33 28-04-2025

NEW YORK , April 28, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law...

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

Shareholder Alert: The Ademi Firm Investigates Whether SpringWorks Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders

10:43 28-04-2025

MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating SpringWorks (Nasdaq: SWTX) for possible ...

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

Germany's Merck Agrees to Buy US Biotech SpringWorks Therapeutics for Almost $4B

7:25 28-04-2025

German drug company Merck KGaA said Monday it has struck a deal to buy U.S. biotech firm SpringWorks...

SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders

SWTX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of SpringWorks Therapeutics, Inc. Is Fair to Shareholders

6:59 28-04-2025

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether t...

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

SpringWorks Therapeutics Announces Expected CHMP Opinion in Q2 2025 for Nirogacestat for the Treatment of Adults with Desmoid Tumors in the European Union

10:35 27-04-2025

STAMFORD, Conn., April 27, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a...

SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?

SpringWorks Therapeutics (SWTX) Soars 9.0%: Is Further Upside Left in the Stock?

9:10 25-04-2025

SpringWorks Therapeutics (SWTX) saw its shares surge in the last session with trading volume being h...

SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz

SpringWorks Therapeutics: Promising Launches, Expanding Pipeline, And M&A Buzz

9:15 11-03-2025

SpringWorks Therapeutics portfolio features Ogsiveo for desmoid tumors and Gomekli for NF1‑plexifo...

SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates

SpringWorks' Q4 Loss Wider Than Expected, Revenues Beat Estimates

11:45 21-02-2025

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witn...

SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates

SpringWorks Therapeutics (SWTX) Reports Q4 Loss, Tops Revenue Estimates

8:46 20-02-2025

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks C...

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates

6:30 20-02-2025

– Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO ® (nirog...

close

SPRINGWORKS THERAPEUTICS ANNOUNCES PUBLICATION OF LONG-TERM EFFICACY AND SAFETY DATA FROM THE PHASE 3 DEFI TRIAL OF OGSIVEO® (NIROGACESTAT) IN ADULTS WITH DESMOID TUMORS IN THE JOURNAL OF CLINICAL ONCOLOGY

21-10-2025
LONG-TERM CONTINUOUS OGSIVEO TREATMENT FOR UP TO 4 YEARS WAS ASSOCIATED WITH FURTHER TUMOR SIZE REDU...
Více zde

EUROPEAN COMMISSION GRANTS APPROVAL OF OGSIVEO® (NIROGACESTAT) FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS

18-08-2025
OGSIVEO IS THE FIRST AND ONLY THERAPY TO RECEIVE MARKETING AUTHORIZATION IN THE EU FOR THE TREATMENT...
Více zde

EUROPEAN COMMISSION GRANTS APPROVAL OF OGSIVEO® (NIROGACESTAT) FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS

18-08-2025
OGSIVEO IS THE FIRST AND ONLY THERAPY TO RECEIVE MARKETING AUTHORIZATION IN THE EU FOR THE TREATMENT...
Více zde

EUROPEAN COMMISSION GRANTS CONDITIONAL APPROVAL OF EZMEKLY® (MIRDAMETINIB) FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN

18-07-2025
– EZMEKLY IS THE FIRST AND ONLY THERAPY TO RECEIVE MARKETING AUTHORIZATION IN THE EU FOR BOTH ADUL...
Více zde

MERCK KGAA, DARMSTADT, GERMANY COMPLETES ACQUISITION OF SPRINGWORKS THERAPEUTICS TO ACCELERATE SUSTAINABLE GROWTH OF ITS HEALTHCARE BUSINESS

01-07-2025
DARMSTADT, GERMANY--(BUSINESS WIRE)--MERCK KGAA, DARMSTADT, GERMANY, A LEADING SCIENCE AND TECHNOLOG...
Více zde

SPRINGWORKS THERAPEUTICS RECEIVES POSITIVE CHMP OPINION FOR NIROGACESTAT FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS

20-06-2025
– IF APPROVED, NIROGACESTAT WILL BE THE FIRST AND ONLY THERAPY WITH MARKETING AUTHORIZATION IN THE...
Více zde

SPRINGWORKS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF SPRINGWORKS THERAPEUTICS, INC. - SWTX

03-06-2025
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, ...
Více zde

SPRINGWORKS THERAPEUTICS RECEIVES POSITIVE CHMP OPINION FOR MIRDAMETINIB FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN

23-05-2025
– IF APPROVED, MIRDAMETINIB IS EXPECTED TO BE THE FIRST AND ONLY THERAPY IN THE EUROPEAN UNION WIT...
Více zde

SPRINGWORKS INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF SPRINGWORKS THERAPEUTICS, INC. - SWTX

30-04-2025
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, ...
Více zde

SHAREHOLDER ALERT: THE M&A CLASS ACTION FIRM INVESTIGATES THE MERGER OF SPRINGWORKS THERAPEUTICS, INC. - SWTX

28-04-2025
NEW YORK , APRIL 28, 2025 /PRNEWSWIRE/ -- MONTEVERDE & ASSOCIATES PC (THE "M&A CLASS ACTION FIRM"),...
Více zde

ALERT: ROWLEY LAW PLLC IS INVESTIGATING PROPOSED ACQUISITION OF SPRINGWORKS THERAPEUTICS, INC.

28-04-2025
NEW YORK , APRIL 28, 2025 /PRNEWSWIRE/ -- ROWLEY LAW PLLC IS INVESTIGATING POTENTIAL SECURITIES LAW...
Více zde

SHAREHOLDER ALERT: THE ADEMI FIRM INVESTIGATES WHETHER SPRINGWORKS THERAPEUTICS, INC. IS OBTAINING A FAIR PRICE FOR ITS PUBLIC SHAREHOLDERS

28-04-2025
MILWAUKEE--(BUSINESS WIRE)--THE ADEMI FIRM IS INVESTIGATING SPRINGWORKS (NASDAQ: SWTX) FOR POSSIBLE ...
Více zde

SWTX STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF SPRINGWORKS THERAPEUTICS, INC. IS FAIR TO SHAREHOLDERS

28-04-2025
NEW YORK--(BUSINESS WIRE)--HALPER SADEH LLC, AN INVESTOR RIGHTS LAW FIRM, IS INVESTIGATING WHETHER T...
Více zde

MERCK KGAA, DARMSTADT, GERMANY TO ACQUIRE SPRINGWORKS THERAPEUTICS TO ACCELERATE SUSTAINABLE GROWTH OF HEALTHCARE BUSINESS

28-04-2025
– PURCHASE PRICE OF $47 PER SHARE IN CASH REPRESENTS AN EQUITY VALUE OF APPROXIMATELY $3.9 BILLION...
Více zde

MERCK KGAA, DARMSTADT, GERMANY, TO ACQUIRE US BIOPHARMA COMPANY SPRINGWORKS THERAPEUTICS TO ACCELERATE SUSTAINABLE GROWTH OF HEALTHCARE BUSINESS

28-04-2025
DARMSTADT, GERMANY--(BUSINESS WIRE)--MERCK KGAA, DARMSTADT, GERMANY (DAX: MRK), A LEADING SCIENCE AN...
Více zde

SPRINGWORKS THERAPEUTICS ANNOUNCES EXPECTED CHMP OPINION IN Q2 2025 FOR NIROGACESTAT FOR THE TREATMENT OF ADULTS WITH DESMOID TUMORS IN THE EUROPEAN UNION

27-04-2025
STAMFORD, CONN., APRIL 27, 2025 (GLOBE NEWSWIRE) -- SPRINGWORKS THERAPEUTICS, INC. (NASDAQ: SWTX), A...
Více zde

SPRINGWORKS THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT BUSINESS UPDATES

20-02-2025
– ACHIEVED $61.5 MILLION AND $172.0 MILLION IN FOURTH QUARTER AND FULL YEAR 2024 OGSIVEO ® (NIROG...
Více zde

SPRINGWORKS THERAPEUTICS AND JEWELRY DESIGNER JENNIFER FISHER TEAM UP TO ENCOURAGE PEOPLE WITH DESMOID TUMORS TO TAKE ACTION BEFORE THEIR TUMOR TAKES OVER

19-02-2025
- EDUCATIONAL CAMPAIGN AIMS TO RAISE AWARENESS AND DRIVE CONVERSATION ABOUT DESMOID TUMORS, THE DEVA...
Více zde

ONCO360 HAS BEEN SELECTED AS A NATIONAL SPECIALTY PHARMACY PARTNER FOR GOMEKLI™ (MIRDAMETINIB), MANUFACTURED BY SPRINGWORKS THERAPEUTICS

17-02-2025
LOUISVILLE, KY., FEB. 17, 2025 (GLOBE NEWSWIRE) -- ONCO360®, THE NATION'S LEADING INDEPENDENT SPECI...
Více zde

UPDATE: SPRINGWORKS THERAPEUTICS ANNOUNCES FDA APPROVAL OF GOMEKLI™ (MIRDAMETINIB) FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN

11-02-2025
– GOMEKLI IS THE FIRST AND ONLY MEDICINE APPROVED FOR BOTH ADULTS AND CHILDREN WITH NF1-PN   – ...
Více zde

SPRINGWORKS THERAPEUTICS ANNOUNCES FDA APPROVAL OF GOMEKLI™ (MIRDAMETINIB) FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS WITH NF1-PN

11-02-2025
– GOMEKLI IS THE FIRST AND ONLY MEDICINE APPROVED FOR BOTH ADULTS AND CHILDREN WITH NF1-PN   – ...
Více zde

SPRINGWORKS THERAPEUTICS TO REPORT FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS ON THURSDAY, FEBRUARY 20, 2025

30-01-2025
STAMFORD, CONN., JAN. 30, 2025 (GLOBE NEWSWIRE) -- SPRINGWORKS THERAPEUTICS, INC. (NASDAQ: SWTX), A ...
Více zde

SPRINGWORKS THERAPEUTICS REPORTS PRELIMINARY FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES AT 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

13-01-2025
– ACHIEVED $61.5 MILLION AND $172.0 MILLION IN PRELIMINARY FOURTH QUARTER AND FULL YEAR 2024 OGSI...
Více zde

SPRINGWORKS THERAPEUTICS TO PRESENT AT THE 43RD ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

03-01-2025
STAMFORD, CONN., JAN. 03, 2025 (GLOBE NEWSWIRE) -- SPRINGWORKS THERAPEUTICS, INC. (NASDAQ: SWTX), A ...
Více zde

SPRINGWORKS THERAPEUTICS TO PARTICIPATE IN THE 7TH ANNUAL EVERCORE ISI HEALTHCONX CONFERENCE

26-11-2024
STAMFORD, CONN., NOV. 26, 2024 (GLOBE NEWSWIRE) -- SPRINGWORKS THERAPEUTICS, INC. (NASDAQ: SWTX), A ...
Více zde

SPRINGWORKS THERAPEUTICS TO PARTICIPATE IN THE JEFFERIES LONDON HEALTHCARE CONFERENCE

12-11-2024
STAMFORD, CONN., NOV. 12, 2024 (GLOBE NEWSWIRE) -- SPRINGWORKS THERAPEUTICS, INC. (NASDAQ: SWTX), A ...
Více zde

SPRINGWORKS THERAPEUTICS REPORTS THIRD QUARTER 2024 FINANCIAL RESULTS AND RECENT BUSINESS HIGHLIGHTS

12-11-2024
– ACHIEVED $49.3 MILLION IN OGSIVEO ® (NIROGACESTAT) NET PRODUCT REVENUE IN THE THIRD QUARTER –...
Více zde

SPRINGWORKS THERAPEUTICS ANNOUNCES MIRDAMETINIB DATA TO BE PRESENTED AT THE 2024 SOCIETY FOR NEURO-ONCOLOGY (SNO) ANNUAL MEETING

11-11-2024
– DATA FROM THE PIVOTAL PHASE 2B RENEU TRIAL DEMONSTRATE THAT PATIENTS WITH NF1-PN ACHIEVED DEEP R...
Více zde

SPRINGWORKS THERAPEUTICS ANNOUNCES PUBLICATION OF THE PIVOTAL PHASE 2B RENEU TRIAL EVALUATING MIRDAMETINIB IN ADULTS AND CHILDREN WITH NF1-PN IN THE JOURNAL OF CLINICAL ONCOLOGY

11-11-2024
– MIRDAMETINIB TREATMENT DEMONSTRATED SIGNIFICANT CONFIRMED OBJECTIVE RESPONSE RATES AND A  MANAG...
Více zde

SPRINGWORKS THERAPEUTICS ANNOUNCES LONG-TERM EFFICACY AND SAFETY DATA FROM PHASE 3 DEFI TRIAL OF OGSIVEO® (NIROGACESTAT) IN ADULTS WITH DESMOID TUMORS TO BE PRESENTED AT THE CONNECTIVE TISSUE ONCOLOGY SOCIETY (CTOS) 2024 ANNUAL MEETING

07-11-2024
– LONG-TERM FOLLOW-UP DATA HIGHLIGHT FURTHER REDUCTIONS IN TUMOR SIZE, INCREASE IN ORR WITH ADDITI...
Více zde

close

Datum Typ Otevřít EDGAR Stáhnout dokument
2025-07-01 01:00:008-KStáhnout
2025-07-01 00:00:008-KStáhnout
2025-06-26 01:00:008-KStáhnout
2025-06-26 00:00:008-KStáhnout
2025-06-16 01:00:008-KStáhnout
2025-06-16 00:00:008-KStáhnout
2025-05-14 01:00:008-KStáhnout
2025-05-14 00:00:008-KStáhnout
2025-05-09 01:00:0010-QStáhnout
2025-05-09 00:00:0010-QStáhnout
2025-04-28 01:00:008-KStáhnout
2025-04-28 00:00:008-KStáhnout
2025-02-20 00:00:008-KStáhnout
2025-02-20 00:00:0010-KStáhnout
2025-02-19 23:00:008-KStáhnout
2025-02-19 23:00:0010-KStáhnout
2025-02-12 00:00:008-KStáhnout
2025-02-11 23:00:008-KStáhnout
2025-01-13 00:00:008-KStáhnout
2025-01-12 23:00:008-KStáhnout
2024-11-12 00:00:008-KStáhnout
2024-11-12 00:00:0010-QStáhnout
2024-11-11 23:00:008-KStáhnout
2024-11-11 23:00:0010-QStáhnout
2024-08-07 01:00:008-KStáhnout
2024-08-07 01:00:0010-QStáhnout
2024-08-07 00:00:008-KStáhnout
2024-08-07 00:00:0010-QStáhnout
2024-07-30 01:00:008-KStáhnout
2024-07-30 00:00:008-KStáhnout
2024-06-07 01:00:008-KStáhnout
2024-06-07 00:00:008-KStáhnout
2024-05-17 01:00:008-KStáhnout
2024-05-17 00:00:008-KStáhnout
2024-05-02 01:00:008-KStáhnout
2024-05-02 01:00:0010-QStáhnout
2024-05-02 00:00:008-KStáhnout
2024-05-02 00:00:0010-QStáhnout
2024-02-27 00:00:008-KStáhnout
2024-02-27 00:00:0010-KStáhnout
2024-02-26 23:00:008-KStáhnout
2024-02-26 23:00:0010-KStáhnout
2024-02-02 00:00:008-KStáhnout
2024-02-01 23:00:008-KStáhnout
2023-12-06 00:00:008-KStáhnout
2023-12-05 23:00:008-KStáhnout
2023-11-28 00:00:008-KStáhnout
2023-11-27 23:00:008-KStáhnout
2023-11-17 00:00:008-KStáhnout
2023-11-16 23:00:008-KStáhnout
2023-11-02 00:00:008-KStáhnout
2023-11-02 00:00:0010-QStáhnout
2023-11-01 23:00:008-KStáhnout
2023-11-01 23:00:0010-QStáhnout
2023-09-01 01:00:008-KStáhnout
2023-09-01 00:00:008-KStáhnout
2023-08-02 01:00:008-KStáhnout
2023-08-02 01:00:0010-QStáhnout
2023-08-02 00:00:008-KStáhnout
2023-08-02 00:00:0010-QStáhnout
2023-06-05 01:00:008-KStáhnout
2023-06-05 00:00:008-KStáhnout
2023-05-25 01:00:008-KStáhnout
2023-05-25 00:00:008-KStáhnout
2023-05-03 01:00:008-KStáhnout
2023-05-03 01:00:0010-QStáhnout
2023-05-03 00:00:008-KStáhnout
2023-05-03 00:00:0010-QStáhnout
2023-03-10 00:00:008-KStáhnout
2023-03-09 23:00:008-KStáhnout
2023-02-28 00:00:008-KStáhnout
2023-02-28 00:00:0010-KStáhnout
2023-02-27 23:00:008-KStáhnout
2023-02-27 23:00:0010-KStáhnout
2022-11-03 00:00:008-KStáhnout
2022-11-03 00:00:0010-QStáhnout
2022-11-02 23:00:008-KStáhnout
2022-11-02 23:00:0010-QStáhnout
2022-09-16 01:00:008-KStáhnout
2022-09-16 00:00:008-KStáhnout
2022-09-12 01:00:008-KStáhnout
2022-09-12 00:00:008-KStáhnout
2022-09-08 01:00:008-KStáhnout
2022-09-08 00:00:008-KStáhnout
2022-09-07 01:00:008-KStáhnout
2022-09-07 00:00:008-KStáhnout
2022-08-04 01:00:008-KStáhnout
2022-08-04 01:00:0010-QStáhnout
2022-08-04 00:00:008-KStáhnout
2022-08-04 00:00:0010-QStáhnout
2022-07-15 01:00:008-KStáhnout
2022-07-15 00:00:008-KStáhnout
2022-06-10 01:00:008-KStáhnout
2022-06-10 00:00:008-KStáhnout
2022-05-20 01:00:008-KStáhnout
2022-05-20 00:00:008-KStáhnout
2022-05-05 01:00:008-KStáhnout
2022-05-05 01:00:0010-QStáhnout
2022-05-05 00:00:008-KStáhnout
2022-05-05 00:00:0010-QStáhnout
2022-02-24 00:00:008-KStáhnout
2022-02-24 00:00:0010-KStáhnout
2022-02-23 23:00:008-KStáhnout
2022-02-23 23:00:0010-KStáhnout
2021-11-04 00:00:008-KStáhnout
2021-11-04 00:00:0010-QStáhnout
2021-11-03 23:00:008-KStáhnout
2021-11-03 23:00:0010-QStáhnout
2021-10-27 01:00:008-KStáhnout
2021-10-27 00:00:008-KStáhnout
2021-08-04 01:00:008-KStáhnout
2021-08-04 01:00:0010-QStáhnout
2021-08-04 00:00:008-KStáhnout
2021-08-04 00:00:0010-QStáhnout
2021-05-24 01:00:008-KStáhnout
2021-05-24 00:00:008-KStáhnout
2021-05-06 01:00:008-KStáhnout
2021-05-06 00:00:008-KStáhnout
2021-05-05 01:00:0010-QStáhnout
2021-05-05 00:00:0010-QStáhnout
2021-02-25 00:00:008-KStáhnout
2021-02-25 00:00:0010-KStáhnout
2021-02-24 23:00:008-KStáhnout
2021-02-24 23:00:0010-KStáhnout
2020-12-15 00:00:008-KStáhnout
2020-12-14 23:00:008-KStáhnout
2020-11-12 00:00:008-KStáhnout
2020-11-12 00:00:0010-QStáhnout
2020-11-11 23:00:008-KStáhnout
2020-11-11 23:00:0010-QStáhnout
2020-10-08 01:00:008-KStáhnout
2020-10-08 00:00:008-KStáhnout
2020-08-12 01:00:008-KStáhnout
2020-08-12 01:00:0010-QStáhnout
2020-08-12 00:00:008-KStáhnout
2020-08-12 00:00:0010-QStáhnout
2020-05-27 01:00:008-KStáhnout
2020-05-27 00:00:008-KStáhnout
2020-05-12 01:00:008-KStáhnout
2020-05-12 01:00:0010-QStáhnout
2020-05-12 00:00:008-KStáhnout
2020-05-12 00:00:0010-QStáhnout
2020-03-12 00:00:008-KStáhnout
2020-03-12 00:00:0010-KStáhnout
2020-03-11 23:00:008-KStáhnout
2020-03-11 23:00:0010-KStáhnout
2019-12-09 00:00:008-KStáhnout
2019-12-08 23:00:008-KStáhnout
2019-11-12 00:00:008-KStáhnout
2019-11-12 00:00:0010-QStáhnout
2019-11-11 23:00:008-KStáhnout
2019-11-11 23:00:0010-QStáhnout
2019-10-11 01:00:008-KStáhnout
2019-10-11 00:00:008-KStáhnout
2019-09-17 01:00:008-KStáhnout
2019-09-17 00:00:008-KStáhnout
preloader